Details

Autor(en) / Beteiligte

• Crespo, Manuel
• Caragol, Isabel
• Falcó, Vicenç
• Ribera, Esteban
• Urban, Susana
• Pahissa, Albert

Titel

Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART

Ist Teil von

• Enfermedades infecciosas y microbiología clínica, 2008, Vol.26 (1), p.27-31

Ort / Verlag

Spain: Elsevier Espana

Erscheinungsjahr

2008

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Objective The efficacy of recombinant interleukin-2 (rIL-2) was assessed in HIV-infected patients with advanced immune suppression and a discordant immune response to highly active antiretroviral therapy (HAART). The primary endpoint was median change in CD4 + T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations. Material and methods In a prospective cohort study, 19 patients with HIV-RNA < 50 copies/mL and < 200 CD4 + T cells/mm3 without a significant increase in the previous 12 months were scheduled to receive 6 cycles of 4.5 × 106 IU subcutaneous rIL-2 daily for 5 consecutive days, every 4 weeks. Results Median age was 43 years, and 64% had a previous AIDS-defining event. Median nadir and baseline CD4 + cell counts were 36 and 99 cells/mm3 , respectively. Three patients discontinued treatment and one experienced grade 4 side effects. CD4 + T-cell counts increased to 147 cells/mm3 (range, 24-285) at 1 month following completion of treatment ( P = 0.002), and 180 cells/mm3 (range, 38-280) at 18 months (P < 0.001). This improvement was associated with a significant decrease in expression rates of the activation markers, HLA-DR and CD38. Conclusion Our results suggest that in patients with advanced HIV-infection showing a blunted immune response to HAART, rIL-2 might increase the pool of CD4 + T-cells by down-regulating the status of immune activation.